Ceres Inc (CERE) Social Stream



Ceres Inc (CERE): $25.20

1.30 (+5.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CERE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 388

in industry

Cerevel Therapeutics Holdings Inc (CERE) Price Targets From Analysts

Use the tables below to see what analysts covering Cerevel Therapeutics Holdings Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-07 3 $39 $33 $36.333 $34.98 3.87%
2021-11-10 3 $50 $37 $42 $34.98 20.07%
2021-12-22 4 $50 $39 $47.25 $34.98 35.08%
2022-03-07 5 $50 $39 $47.8 $34.98 36.65%

The Trend in the Analyst Price Target


CERE's average price target has moved up $30.8 over the prior 16 months.

Over the past 47 weeks, CERE's average upside potential has been 50.42%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-12 2 23 21 22.000 13.57 62.12%
2021-10-07 3 39 33 36.333 32.58 11.52%
2021-11-10 3 50 37 42.000 38.67 8.61%
2021-12-16 4 50 39 47.250 29.21 61.76%
2022-02-01 5 50 39 47.800 27.08 76.51%

CERE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.1 4 1 0 0 0 5

The Trend in the Broker Recommendations


CERE's average broker recommendation rating improved by 0.13 over the prior 120 days.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • Cerevel Therapeutics Holdings Inc's number of analysts covering the stock is higher than 108.35% of all US stocks.
  • In terms of how Cerevel Therapeutics Holdings Inc fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 81.74% of that group.
  • In terms of how Cerevel Therapeutics Holdings Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -10.18% of that group.
  • In the context of Pharmaceutical Products stocks, Cerevel Therapeutics Holdings Inc's average analyst price target is greater than 388% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Cerevel Therapeutics Holdings Inc are CCXI, BPMC, and BHVN.

Make investment decisions regarding CERE using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8711 seconds.